<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307720</url>
  </required_header>
  <id_info>
    <org_study_id>AGONIST TRIGGER</org_study_id>
    <nct_id>NCT03307720</nct_id>
  </id_info>
  <brief_title>Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)</brief_title>
  <official_title>Agonist Trigger Versus Classical HCG Trigger in Controlled Ovarian Stimulation Among Three Different Subsets of Patients (Poor Responders, Normoresponders and High Responders)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ginegorama S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ginegorama S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Agonist triggering in controlled ovarian stimulation protocols is being used during last&#xD;
      years (among high responder patients to avoid OHSS).&#xD;
&#xD;
      Indeed, agonist triggering is more physiologic than HCG triggering. Investigators propose to&#xD;
      compare the effectiveness of both types of trigger among three different subsets of patients:&#xD;
&#xD;
        1. Poor responders.&#xD;
&#xD;
        2. Normo-responders&#xD;
&#xD;
        3. High responders Comparing both the number and the quality of achieved oocytes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the last years, ovulation triggering in controlled ovarian stimulation protocols has&#xD;
      been used specially to avoid hyperstimulation syndromes (OHSS). Indeed, the substitution of&#xD;
      the classical HCG triggering by the agonist one, reduces almost to zero the risk of OHSS.&#xD;
&#xD;
      On the other hand poor responder patients to ovarian stimulation represent a challenge in&#xD;
      assisted reproduction. Defining poor responders is not easy, but we can define them as those&#xD;
      patients with less than 4 eggs obtained after oocyte retrieval.&#xD;
&#xD;
      Different strategies have been proposed to overcome this problem. In other words, to obtain&#xD;
      more oocytes. These include an increase in FSH doses, an increase in FSH action by adding&#xD;
      sensitizers agents.&#xD;
&#xD;
      Among the possible strategies, investigators propose the agonist triggering. HCG (classical)&#xD;
      triggering represents the use of a LH-like product (with a prolonged action). The&#xD;
      administration of a GnRH agonist provoke the production and liberation of both FSH and LH.&#xD;
      Thus, the pro-ovulatory action is more physiologic , and possibly, more effective.&#xD;
&#xD;
      So, the use of a triggering protocol that nowadays is being used among high responders (thus&#xD;
      reducing the OHSS risk) is proposed for both poor responder and normo-responder patients&#xD;
      trying to achieve more oocytes, and specifically more mature oocytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 18, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>IVF patients enrolled either to HCG or agonist trigger ovulation induction</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mature oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of mature oocytes achieved after oocyte retrieval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relation mature oocytes/punctured oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Relation between the number of mature oocytes and the follicles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilized oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relation fertilized oocytes/achieved Mature oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Relation between the number of fertilized oocytes and the mature oocytes achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blastocysts developed</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of blastocysts developed in each arm of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancelled cycles</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Percentage of cancelled cycles</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ovulation Induction</condition>
  <condition>In Vitro Fertilization (IVF)</condition>
  <condition>Infertility, Female</condition>
  <condition>Oocytes</condition>
  <arm_group>
    <arm_group_label>Poor responders. Classical trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.&#xD;
Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor responders. Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)&#xD;
Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normo responders. Classical trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.&#xD;
Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normo responders. Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)&#xD;
Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High responders. Classical trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.&#xD;
Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High responders. Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)&#xD;
Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin Releasing Hormone Agonists (GNRH-A)</intervention_name>
    <description>Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.</description>
    <arm_group_label>High responders. Agonist trigger</arm_group_label>
    <arm_group_label>Normo responders. Agonist trigger</arm_group_label>
    <arm_group_label>Poor responders. Agonist trigger</arm_group_label>
    <other_name>Agonist trigger</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human chorionic gonadotropin</intervention_name>
    <description>Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.</description>
    <arm_group_label>High responders. Classical trigger</arm_group_label>
    <arm_group_label>Normo responders. Classical trigger</arm_group_label>
    <arm_group_label>Poor responders. Classical trigger</arm_group_label>
    <other_name>HCG trigger</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women scheduled for IVF treatment.&#xD;
&#xD;
          -  First ovarian stimulation&#xD;
&#xD;
          -  Two ovaries present&#xD;
&#xD;
          -  No previous ovarian surgery&#xD;
&#xD;
          -  No contraindication for any of the assigned treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ovarian surgery.&#xD;
&#xD;
          -  Previous IVF treatments.&#xD;
&#xD;
          -  Absence of one ovary&#xD;
&#xD;
          -  Presence of an endometrioma&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gorka Barrenetxea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon Iker Arambarri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gorka Barrenetxea, PhD</last_name>
    <phone>00 34 605711484</phone>
    <email>gbarrenetxea@reproduccionbilbao.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amaia Garcia, PhD</last_name>
    <email>agarcia@reproduccionbilbao.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproduccion Bilbao Assisted Reproduction Center</name>
      <address>
        <city>Bilbao</city>
        <state>Bizkaia</state>
        <zip>48014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ginegorama S.L.</investigator_affiliation>
    <investigator_full_name>Gorka Barrenetxea</investigator_full_name>
    <investigator_title>Professor of Gynecology &amp; Obstetrics Universidad del País Vasco/Euskal Herriko Unibertsitatea. Medical Director of Reproducción Bilbao</investigator_title>
  </responsible_party>
  <keyword>agonist trigger</keyword>
  <keyword>Ovulation induction</keyword>
  <keyword>Controlled ovarian stimulation (COS)</keyword>
  <keyword>Poor responder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

